RUNX1T1 and neoplasm: ERK1/2 signaling promotes cell proliferation in response to extracellular signaling, in addition, it is activated by ETO and leads to chemoresistance in the tumor.43 It is known that supernumerary centrosomes contribute to chemoresistance and poor outcome in tumor cells.44 Here, we showed that ETO treatment activated ERK1/2, followed by centrosome amplification in ACT cells.